Wechselwirkungen von Aztreonam
Aztreonam (Azactam, Cayston), ein Antibiotikum, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 46 dokumentierte Wechselwirkungen: 0 schwerwiegende, 46 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.
Wechselwirkungen laut Fachinformation
Mittelschwere Wechselwirkungen (46)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)
Prüfen Sie Aztreonam gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.